First performance study of ETEST® TBP (Tebipenem) for Minimum Inhibitory Concentration (MIC) determination for Enterobacterales Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS Efficacy of Tebipenem Pivoxil Hydrobromide in Patients with Complicated Urinary Tract Infection and/or Acute Pyelonephritis and Associated Bacteremia in ADAPT-PO Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS Activity of Tebipenem against Escherichia coli collected from Urinary Tract Infections in Europe in 2020 Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model Posted on September 29, 2021 at 6:19 pm.Written by Spero Therapeutics Empiric Antimicrobial Prescribing for Urinary Tract Infections in Patients Discharged from the Emergency Department Posted on September 29, 2021 at 10:45 am.Written by Spero Therapeutics Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease Posted on October 27, 2020 at 3:46 pm.Written by Spero Therapeutics Activity of SPR206, a Polymyxin Derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains Posted on October 27, 2020 at 3:46 pm.Written by Spero Therapeutics SPR720, A Novel Aminobenzimidazole Gyrase Inhibitor, Demonstrates Potent Efficacy Against Mycobacterium avium ATCC 700898 in a Chronic C3HeBFeJ Mouse Infection Model Posted on October 27, 2020 at 3:45 pm.Written by Spero Therapeutics Evaluating the Activity of SPR719 a Novel Aminobenzimidazole against Nontuberculous Mycobacteria Posted on October 27, 2020 at 3:45 pm.Written by Spero Therapeutics Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics- Pharmacodynamics in a Neutropenic Murine Acute Pyelonephritis Model Posted on October 27, 2020 at 3:44 pm.Written by Spero Therapeutics 1 2 3 4 5 6 … 9 »
First performance study of ETEST® TBP (Tebipenem) for Minimum Inhibitory Concentration (MIC) determination for Enterobacterales Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS
Efficacy of Tebipenem Pivoxil Hydrobromide in Patients with Complicated Urinary Tract Infection and/or Acute Pyelonephritis and Associated Bacteremia in ADAPT-PO Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS
Activity of Tebipenem against Escherichia coli collected from Urinary Tract Infections in Europe in 2020 Posted on April 21, 2022 at 8:05 am.Written by SPERO THERAPEUTICS
Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model Posted on September 29, 2021 at 6:19 pm.Written by Spero Therapeutics
Empiric Antimicrobial Prescribing for Urinary Tract Infections in Patients Discharged from the Emergency Department Posted on September 29, 2021 at 10:45 am.Written by Spero Therapeutics
Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease Posted on October 27, 2020 at 3:46 pm.Written by Spero Therapeutics
Activity of SPR206, a Polymyxin Derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains Posted on October 27, 2020 at 3:46 pm.Written by Spero Therapeutics
SPR720, A Novel Aminobenzimidazole Gyrase Inhibitor, Demonstrates Potent Efficacy Against Mycobacterium avium ATCC 700898 in a Chronic C3HeBFeJ Mouse Infection Model Posted on October 27, 2020 at 3:45 pm.Written by Spero Therapeutics
Evaluating the Activity of SPR719 a Novel Aminobenzimidazole against Nontuberculous Mycobacteria Posted on October 27, 2020 at 3:45 pm.Written by Spero Therapeutics
Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics- Pharmacodynamics in a Neutropenic Murine Acute Pyelonephritis Model Posted on October 27, 2020 at 3:44 pm.Written by Spero Therapeutics
